Solna, Sweden, October 6 th, 2010 -- CMA Microdialysis AB (CMA) today announced the introduction of the new CE-approved EirusTM Tissue monitoring system. Eirus enables second-by-second monitoring of organ specific biochemistry in the hospital setting. Monitoring tissue chemistry provides early warning of critical conditions allowing for preemptive interventions and improved patient care.
Millions of patients develop local ischemia in the brain and other critical tissues following surgery and other types of injuries. Cerebral ischemia is the third leading cause of death in the Western World.
Ischemia occurs when there is insufficient blood flow to an organ to meet the metabolic demand. It is therefore highly essential to continuously monitor the metabolic state of a specific organ at risk, rather than just global biomarkers in the blood.
The new Eirus TM Tissue system monitors biochemistry locally in specific tissue and in the brain. Eirus continuously monitors interstitial glucose and lactate by using minimally invasive microdialysis catheters connected to the Eirus disposable biosensor.
“Following years of research & development, it is an honor to introduce CMA’s 4th generation system representing a major landmark in clinical monitoring as the first truly continuous tissue monitoring system intended for ICU use”, comments Philip Siberg, CEO of CMA.
Eirus Tissue is CE-approved for monitoring adipose tissue, resting skeleton muscle and the brain.
In 2009, the Eirus platform gained initial CE-approval for continuous glucose and lactate monitoring in blood. During 2009-2010, numerous clinical studies have verified the accuracy and performance of the system with excellent outcome. Eirus Tissue, the next natural step of the platform, will be selectively launched in Scandinavia during 2010 and broader in Europe during 2011.
For more info on the Eirus platform, please contact Mrs. Anna Redwood, Product Manager Eirus on +46 70 883 0474 asv@microdialysis.se or Philip Siberg, CEO, on +46 70 7906734 psi@microdialysis.se
About CMA Microdialysis AB
CMA is a Swedish medical device and life science company founded in 1984. Unique and market leading solutions are developed, produced and sold to clinicians and researchers to enable optimized patient care and accelerated drug development. CMA’s complete line of instruments, consumables and computer software are used globally by universities, hospitals and pharmaceutical companies as unique tools for in vivo sampling and monitoring of organs and blood. The head office is located outside Stockholm, Sweden, with a subsidiary in Boston, US. CMA has distributors across the globe, responsible for local sales, service and support. CMA is primarily owned by Investor AB and Bure AB, both leading Swedish industrial holding companies listed on the Stockholm Stock Exchange. For more info, see www.microdialysis.se
